Author: Oxford BioTherapeutics

Oxford BioTherapeutics’ Third Partnered Programme with Boehringer Ingelheim Enters the Clinic and its First (Obrixtamig) Advances to Phase 3

June 22, 2026
Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours

April 9, 2026

Oxford BioTherapeutics’ Third Partnered Programme with Boehringer Ingelheim Enters the Clinic and its First (Obrixtamig) Advances to Phase 3